tiprankstipranks
Advertisement
Advertisement
Akebia Therapeutics Earnings Call: Vafseo Drives Transition
PremiumCompany AnnouncementsAkebia Therapeutics Earnings Call: Vafseo Drives Transition
2M ago
Akebia Therapeutics Balances Vafseo Momentum With Headwinds
Premium
Company Announcements
Akebia Therapeutics Balances Vafseo Momentum With Headwinds
2M ago
Akebia reports Q1 EPS (3c), consensus 0c
Premium
The Fly
Akebia reports Q1 EPS (3c), consensus 0c
3M ago
3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts
PremiumMarket News3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts
5M ago
Akebia reports Q4 EPS (5c), consensus (4c)
Premium
The Fly
Akebia reports Q4 EPS (5c), consensus (4c)
5M ago
Akebia price target lowered to $4 from $5 at BTIG
Premium
The Fly
Akebia price target lowered to $4 from $5 at BTIG
5M ago
Akebia announces corporate updates, 2026 pipeline outlook
PremiumThe FlyAkebia announces corporate updates, 2026 pipeline outlook
6M ago
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
Premium
Company Announcements
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
6M ago
Akebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
Premium
Ratings
Akebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100